Date: 2014-05-30
Type of information: Private placement
Company: BiolineRx (Israel)
Investors: Lincoln Park Capital Fund (USA)
Amount: up to $20 million
Funding type: private placement
Planned used:
Others: * On May 30, 2014, BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced that it has signed a purchase agreement for the sale, from time to time, of up to $20 million of its American Depositary Shares (“ADSs”) with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. During the 36-month term of the purchase agreement, BioLineRx controls the timing and amount of any sales to LPC, if and when the Company decides, in accordance with the purchase agreement. LPC has no right to require the Company to sell any ADSs to LPC, but LPC is obligated to make purchases as BioLineRx directs, subject to certain conditions. Such conditions include the effectiveness of a registration statement to be filed with the U.S. Securities and Exchange Commission covering the resale of the ADSs that may be issued to LPC. The purchase price related to any sales to LPC will be based on the prevailing market prices of the Company’s ADSs immediately preceding the notice of sale to LPC, without any fixed discount. The agreement may be terminated by the Company at any time, at its sole discretion, without any cost or penalty.
Therapeutic area: Cancer - Oncology - Infectious diseases - Digestive diseases - Inflammatory diseases - Dermatological diseases - Metabolic diseases
